论文部分内容阅读
目的 :探讨和分析白血病bcl- 2 ,p170 ,CD34 表达的临床意义及其相关性。方法 :用ABC免疫细胞化学法检测 77例急性白血病和 2 3例慢性粒细胞白血病bcl- 2 ,p170 ,CD34 的表达。结果 :复发、难治急性白血病bcl- 2 ,p170 ,CD34 的表达率明显高于初治急性白血病 ;bcl- 2 ,p170 ,CD34 高表达的急性白血病完全缓解率显著低于不表达或低表达者 ;加速 /急变期的慢性粒细胞白血病CD34 表达高于慢性期 ;bcl- 2高表达的阳性符合率为 90 .9% ,略高于p170或CD34 ;白血病bcl- 2 ,p170的表达有轻度正相关性 (r =0 .3 86,P <0 .0 0 1)。 结论 :bcl- 2为较敏感的临床预测指标 ,联合检测bcl- 2 ,p170 ,CD34 可能提高单一指标的预测价值。CD34 可能是CML病程进展的指标。而不同多药耐药机制可能有一定的联系
Objective: To investigate and analyze the clinical significance and correlation of bcl-2, p170 and CD34 expression in leukemia. Methods : The expression of bcl-2, p170 and CD34 in 77 cases of acute leukemia and 23 cases of chronic myelogenous leukemia was detected by ABC immunocytochemistry. Results: The expression rates of bcl-2, p170 and CD34 in relapsed and refractory acute leukemia were significantly higher than those in newly diagnosed acute leukemia; the complete remission rate of acute leukemia with high expression of bcl-2, p170 and CD34 was significantly lower than that of non-expressed or low-expressed patients. The rate of CD34 expression in chronic myelogenous leukemia was higher than that in chronic phase in accelerated/faded stage; the positive rate of high expression of bcl-2 was 90.9%, slightly higher than that of p170 or CD34; bcl-2 was leukemia, and the expression of p170 was mild. Positive correlation (r = 0.386, P <0. 0 01). Conclusion : bcl-2 is a sensitive clinical predictor. Combined detection of bcl-2, p170 and CD34 may increase the predictive value of a single index. CD34 may be an indicator of the progression of CML. And the different multidrug resistance mechanisms may have a certain connection